Abstract:Epstein-Barr virus (EBV) is an important cause of human lymphomas, including Burkitt lymphoma (BL). EBV+ BLs are driven by Myc translocation and have stringent forms of viral latency that do not express either of the two major EBV oncoproteins, EBNA2 (which mimics Notch signaling) and LMP1 (which activates NF-κB signaling). Suppression of Myc-induced apoptosis, often through mutation of the TP53 (p53) gene or inhibition of pro-apoptotic BCL2L11 (BIM) gene expression, is required for development of Myc-driven BLs. EBV+ BLs contain fewer cellular mutations in apoptotic pathways compared to EBV-negative BLs, suggesting that latent EBV infection inhibits Myc-induced apoptosis. Here we use an EBNA2-deleted EBV virus (ΔEBNA2 EBV) to create the first in vivo model for EBV+ BL-like lymphomas derived from primary human B cells. We show that cord blood B cells infected with both ΔEBNA2 EBV and a Myc-expressing vector proliferate indefinitely on a CD40L/IL21 expressing feeder layer in vitro and cause rapid onset EBV+ BL-like tumors in NSG mice. These LMP1/EBNA2-negative Myc-driven lymphomas have wild type p53 and very low BIM, and express numerous germinal center B cell proteins (including TCF3, BACH2, Myb, CD10, CCDN3, and GCSAM) in the absence of BCL6 expression. Myc-induced activation of Myb mediates expression of many of these BL-associated proteins. We demonstrate that Myc blocks LMP1 expression both by inhibiting expression of cellular factors (STAT3 and Src) that activate LMP1 transcription and by increasing expression of proteins (DNMT3B and UHRF1) known to enhance DNA methylation of the LMP1 promoters in human BLs. These results show that latent EBV infection collaborates with Myc over-expression to induce BL-like human B-cell lymphomas in mice. As NF-κB signaling retards the growth of EBV-negative BLs, Myc-mediated repression of LMP1 may be essential for latent EBV infection and Myc translocation to collaboratively induce human BLs. EBV is a human gamma herpesvirus that causes infectious mononucleosis and cooperates with translocation of the Myc oncogene to induce Burkitt lymphoma (BL). EBV-infected BLs are derived from germinal center B cells and contain highly latent forms of EBV infection that do not express the two major EBV oncogenes, EBNA2 and LMP1. It has been difficult to model how latent EBV infection cooperates with Myc translocation to form BLs, as EBV cannot transform B cells in vitro in the absence of EBNA2 or LMP1. Here we show that human cord blood B cells co-infected with both an EBNA2-deleted EBV mutant and a Myc-expressing retrovirus form BL-like tumors in immunosuppressed mice, while cells infected with EBNA2-deleted EBV alone or the Myc-expressing retrovirus alone do not. These BL-like tumors express many cellular genes over-expressed in human BLs (including genes associated with a germinal center B cell phenotype) and do not express either EBNA2 or LMP1. Furthermore, we show that Myc blocks expression of the highly immunogenic LMP1 protein in BLs by inhibiting the transcriptional activator, STAT3. This new model should be useful for dissecting the mechanisms by which latent EBV infection and Myc translocation cooperatively induce human BLs.

A New Model of Epstein-Barr Virus Infection Reveals an Important Role for Early Lytic Viral Protein Expression in the Development of Lymphomas

An Epstein-Barr Virus (EBV) Mutant with Enhanced BZLF1 Expression Causes Lymphomas with Abortive Lytic EBV Infection in a Humanized Mouse Model

Epstein-Barr Virus Lytic Infection Contributes to Lymphoproliferative Disease in A Scid Mouse Model

Epstein–Barr virus facilitates the malignant potential of immortalized epithelial cells: from latent genome to viral production and maintenance

LMP1-deficient Epstein-Barr Virus Mutant Requires T Cells for Lymphomagenesis

Epstein|[ndash]|Barr virus facilitates the malignant potential of immortalized epithelial cells: from latent genome to viral production and maintenance

Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice

Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis

The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines

The Epstein-Barr Virus Regulome in Lymphoblastoid Cells.

Epstein–Barr Virus (EBV) Provides Survival Factors to EBV+ Diffuse Large B‐cell Lymphoma (DLBCL) Lines and Modulates Cytokine Induced Specific Chemotaxis in EBV+ DLBCL

Epstein-Barr virus reactivation induces divergent abortive, reprogrammed, and host shutoff states by lytic progression

Uncovering early events in primary Epstein-Barr virus infection using a rabbit model

The Epstein-Barr Virus Glycoprotein BDLF2 Is Essential for Efficient Viral Spread in Stratified Epithelium

Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases

Epstein–Barr Virus B Cell Growth Transformation: the Nuclear Events

Exogenous but not endogenous EBV induces lymphomas in beige/nude/xid mice carrying human lymphoid xenografts

RNA Sequencing Analyses of Gene Expression During Epstein-Barr Virus Infection of Primary B Lymphocytes

Epstein-Barr Virus Orchestrates Spatial Reorganization and Immunomodulation within the Classic Hodgkin Lymphoma Tumor Microenvironment

Epstein-Barr virus infection leads to partial phenotypic reversion of terminally differentiated malignant B cells